Candel Therapeutics, Inc. (NASDAQ:CADL)
| Market Cap | 596.08M+44.3% |
| Revenue (ttm) | 0 |
| Net Income | -88.53M-299.9% |
| EPS | -1.41-137.7% |
| Shares Out | 76.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 848,176 |
| Open | 8.17 |
| Previous Close | 8.03 |
| Day's Range | 7.74 - 8.17 |
| 52-Week Range | 4.35 - 14.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 23.33(+199.49%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CADL
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating CADL in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 12, 2026Earnings report
Ask Barron about CADL
$CADL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CADL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CADL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CADL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CADL Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Clinical development | $13.08M | 57.03% |
| Employee-related | $5.83M | 25.41% |
| Commercial readiness | $2.40M | 10.48% |
| Professional and consulting fees | $1.20M | 5.22% |
| Facility and equipment costs | $377.00K | 1.64% |
| Pre-clinical research | $25.00K | 0.11% |
| Grant income | $22.00K | 0.10% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CADL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CADL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CADL
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $21.74M |
| XBIState Street SPDR S&P Biotech ETF | $18.91M |
| IWMiShares Russell 2000 ETF | $12.93M |
| VXFVanguard Extended Market ETF | $8.32M |
| IWOiShares Russell 2000 Growth ETF | $4.40M |
| VTWOVanguard Russell 2000 ETF | $3.85M |
Estimated from each fund’s disclosed top holdings × AUM
CADL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CADL’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score